Replies to post #287098 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

I got the message, sorry you didn't...

[nidan7500]

He sure did:
Nidan

Quote:
Christopher U Missling, PhD, President & Chief Executive Officer of Anavex, “Our strategy has been consistently to advance ANAVEX®2-73 (blarcamesine) with focus on Precision Medicine and to validate this approach in clinical studies in patients with significant cognitive impairments. We are pleased with these PDD study results that will be further supplemented by actigraphy movement data and whole genome exome DNA and RNA data. Finally, we would like to thank all the patients and participating families as well the investigators and clinical site coordinators for their dedication to this study.”


I read this quote as a message on learning HOW TO Precisely MEASURE PDD in a rational, digital/fact based manner. This is the kind of development (new knowledge) that happens when any envelope is being pushed. We might recognize it as a statement declaring a significant (previously unknown) metric which has to be developed/studied/understood. AKA an "unknown , unknown".
-IMO.

Let's not jump to a failure conclusion yet. Give the AVXL team and supporters a little credit.